Why does a young adult patient with attention deficit hyperactivity disorder (ADHD) experience tachycardia to 120bpm upon standing while taking lisdexamfetamine (Vyvanse) 20mg, despite having a normal resting heart rate?

Orthostatic Tachycardia on Lisdexamfetamine

Your patient is experiencing a normal cardiovascular response to lisdexamfetamine that is being unmasked or exaggerated upon standing—this represents either initial orthostatic hypotension with compensatory tachycardia or postural orthostatic tachycardia syndrome (POTS) triggered by the sympathomimetic effects of the stimulant. 1, 2, 3

Understanding the Mechanism

Lisdexamfetamine causes predictable increases in heart rate and blood pressure through its sympathomimetic effects after conversion to d-amphetamine. 1, 4, 5 However, the specific pattern you're describing—normal resting heart rate but tachycardia to 120 bpm upon standing—suggests an orthostatic component rather than simple stimulant-induced tachycardia. 3

The most likely explanations are:

• Initial orthostatic hypotension with compensatory tachycardia: Blood pressure drops transiently within 15 seconds of standing (>40 mmHg systolic or >20 mmHg diastolic), triggering a compensatory heart rate increase to 120 bpm. 3 The stimulant may be impairing the normal autonomic compensation mechanisms or exaggerating the heart rate response.

• POTS-like response: Inappropriate heart rate increase (≥30 bpm or to >120 bpm) within 10 minutes of standing without significant blood pressure drop. 3 Young adults, particularly women, are overrepresented in POTS, and stimulants can unmask or worsen this condition through their hyperadrenergic effects. 3

• Enhanced sympathetic response: Lisdexamfetamine increases heart rate by an average of 1-2 bpm, but 5-15% of patients experience more substantial increases. 1, 6 Your patient may be in this subset, with the effect becoming most apparent during orthostatic stress when sympathetic activation is already heightened.

Immediate Assessment Required

Measure orthostatic vital signs properly to characterize this phenomenon: 2, 3

• Obtain supine blood pressure and heart rate after 5 minutes of rest
• Have patient stand and immediately measure blood pressure and heart rate at 0-15 seconds (captures initial orthostatic hypotension)
• Repeat measurements at 1 minute and 3 minutes (captures classical orthostatic hypotension)
• Continue to 10 minutes if symptoms persist (captures delayed orthostatic hypotension and POTS)

Document the blood pressure response alongside the heart rate. 3 If blood pressure drops significantly (>20/10 mmHg) with the tachycardia, this represents orthostatic hypotension with compensatory tachycardia. 3 If heart rate increases to 120 bpm without significant blood pressure drop, this suggests POTS. 3

Clinical Management Algorithm

If initial orthostatic hypotension is confirmed (BP drop >40/20 mmHg within 15 seconds): 3

• This is common in young, asthenic subjects and can be exacerbated by stimulants 3
• Counsel on rising slowly from supine/sitting positions
• Ensure adequate hydration (2-3 liters daily)
• Consider reducing lisdexamfetamine dose to 10 mg if symptoms are bothersome
• If symptoms persist despite conservative measures, consider switching to non-stimulant options

If POTS pattern is confirmed (HR increase ≥30 bpm or to >120 bpm without BP drop): 3

• POTS is more common in young women and can be triggered or worsened by stimulants 3
• Implement non-pharmacologic measures: increased fluid intake (2-3 liters daily), increased salt intake (6-10 grams daily), compression stockings, physical countermaneuvers
• Consider dose reduction of lisdexamfetamine
• If ADHD symptoms remain inadequately controlled with lower stimulant dose, switch to atomoxetine or extended-release guanfacine, which do not cause tachycardia and may actually help with orthostatic symptoms 6, 7

If classical orthostatic hypotension develops (BP drop >20/10 mmHg within 3 minutes): 3

• Evaluate for volume depletion, medication effects, or autonomic dysfunction 3
• Stimulants can impair compensatory vasoconstriction in susceptible individuals 3
• Consider switching to non-stimulant ADHD medications, particularly guanfacine, which may actually improve orthostatic tolerance through its alpha-2 agonist effects 6, 7

Cardiovascular Monitoring Considerations

This patient requires more frequent monitoring than standard protocols: 1, 6

• Recheck orthostatic vital signs at each follow-up visit
• Monitor for symptoms of orthostatic intolerance: lightheadedness, dizziness, visual disturbances, fatigue, palpitations 3
• Ensure baseline cardiac history was obtained, including personal history of syncope, chest pain, palpitations, and family history of sudden cardiac death, arrhythmias, or cardiomyopathy 6, 8

The cardiovascular effects of lisdexamfetamine are generally mild and clinically insignificant in most patients, with average increases of only 1-2 bpm for heart rate and 1-4 mmHg for blood pressure. 1, 6, 9 However, your patient's 120 bpm heart rate upon standing places them in the 5-15% subset experiencing more substantial cardiovascular responses. 1, 6

When to Switch Medications

Consider switching to non-stimulant ADHD medications if: 6

• Orthostatic symptoms are bothersome despite conservative measures and dose reduction
• Heart rate consistently exceeds 120 bpm upon standing
• Patient develops syncope or presyncope
• Blood pressure becomes difficult to control

Preferred non-stimulant alternatives: 6, 7

• Atomoxetine: Minimal impact on blood pressure compared to stimulants, provides 24-hour symptom control 6
• Extended-release guanfacine: May actually help lower heart rate and blood pressure through alpha-2 agonist effects, particularly beneficial for patients with orthostatic intolerance 6, 7

Important Caveats

Do not abruptly discontinue lisdexamfetamine if switching medications—taper gradually to avoid rebound symptoms, though physical dependence is less common at therapeutic doses. 4

This orthostatic tachycardia does not indicate serious cardiac pathology in the absence of other concerning symptoms (chest pain, syncope, dyspnea) or abnormal cardiac history. 6, 8, 9 Large population studies demonstrate that stimulants do not increase risk of myocardial infarction, sudden cardiac death, or stroke in the general population. 6, 9

Routine ECG is not indicated unless the patient has concerning cardiac symptoms, abnormal cardiac history, or family history of sudden cardiac death or inherited arrhythmia syndromes. 6, 8 The American Academy of Pediatrics explicitly opposes routine ECG screening before stimulant initiation. 6